Single-question low back pain severity assessment accurate

Single-question low back pain severity assessment accurate
Patient-reported chronic low-back pain severity, based on answering a single question, provides an accurate indicator of patient-reported health status, according to a study published in the February issue of the Journal of Spinal Disorders & Techniques.

(HealthDay)—Patient-reported chronic low-back pain (CLBP) severity, based on answering a single question, provides an accurate indicator of patient-reported health status, according to a study published in the February issue of the Journal of Spinal Disorders & Techniques.

Alesia B. Sadosky, Ph.D., M.P.H., M.B.A., from Global Health Economics and Outcomes Research at Pfizer Inc. in New York City, and colleagues analyzed data from the 2009 Adelphi Disease Specific Programme, in which reported the severity of their CLBP condition by answering a single question: "Please rate how your CLBP condition is today." Patient reported severity (mild, moderate, or severe) was assessed with respect to scores on standard patient self-report measures of and function.

The researchers found that, of the 1,363 survey respondents (49 percent male; mean age, 54.8 years; 52 percent employed at least part time), 28.6, 53.3, and 18.2 percent, respectively, reported mild, moderate, and severe CLBP. As the severity of CLBP increased, there were significant differences observed in increased pain, pain interference with function, and CLBP-linked impairment while working, mainly due to presenteeism. There were higher costs related to lost work productivity resulting from increased work impairment, with estimated annual lost productivity costs of $7,080 per patient for mild CLBP, $16,616 for moderate CLBP, and $25,032 for CLBP. CLBP severity was inversely associated with patient satisfaction with pain-related medication.

"The association between patient-reported CLBP severity and other patient-reported outcomes demonstrates that in the clinical setting, patient-reported CLBP severity provides an accurate and suitable indicator of patient-reported ," the authors write.

Several authors are employed by or disclosed financial ties to Pfizer and Adelphi. The study was supported by Pfizer.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Ebola drugs: A factfile

35 minutes ago

There is no licensed treatment or vaccine for Ebola, which has killed more than 3,300 people in West Africa since the start of 2014.

MRSA biofilms in joint fluid make infections tough to tackle

56 minutes ago

Physicians have long speculated at the hard-to-treat nature of joint infection. In an article published in Journal of Infectious Diseases, Thomas Jefferson University scientists, in collaboration with scientists at the Na ...

Officials ask about 80 to watch for Ebola symptoms

2 hours ago

Health officials in Texas have reached out to about 80 people who may have had direct or indirect contact with the man infected with Ebola or someone close to him, a Dallas County Health and Human Services ...

User comments